Anest. intenziv. Med. 2007;18(3):164-169

Extended immunologic profile taken during the first days in the ICU and the prognosis of patients requiring long-term intensive careIntensive Care Medicine - Original Paper

L. Dadák1, M. Štouračová2, P. Štětka1, P. Kuklínek2, V. Šrámek1
1 Anesteziologicko-resuscitační klinika Fakultní nemocnice u svaté Anny v Brně
2 Ústav imunologie a alergologie Fakultní nemocnice u svaté Anny v Brně

Objective:
To establish the predictive value of an extended spectrum of immunologic parameters measured during the initial ICU days on the ICU survival of patients requiring long-term intensive care.

Design:
Prospective, clinical study.


Setting:
Department Anaesthesia and Intensive Care, St. Anna University Hospital, Brno, Czech Republic.

Material and methods:
The immune profile was taken in patients estimated to stay in the ICU > 3 days in 5- day intervals. In this paper we report on the trends of TNF-alpha production of the whole blood after LPS stimulation (TNF-alpha), plasma IL-6 and IL-10 concentrations and T-lymphocyte activation (CD3+HLADR+) in the first 5 days of ICU stay. The relationship of the immunologic parameters to ICU mortality, type of admission (surgical, medical, trauma, CPR) and APACHE II is also reported.

Results:
167 patients were studied [M/F 113/54; mean age 63 (53; 73) years]. 137 survived their ICU stay (S) and 30 died (NS). APACHE II on admission was 27 (21; 33). On day 1 the production of TNF-alpha differed in the S and NS groups [> 1000 pg/ml (752; > 1000) and 870 pg/ml (542; > 1000) respectively; p < 0.05] as did the IL-10 concentration [6.2 pg/ml (5; 18) and 19 pg/ml (5.4; 63) respectively; p=0.005]. In the patients remaining in the ICU on day 5 (n=125) the change in TNF-α between day 1 and day 5 (delta TNF-α) did not differ between the S and NS groups.There was no significant difference between TNF-alpha between the S and NS groups on day 5 [in group S TNF-alpha production increased from > 1000 pg/ml (752; > 1000) to > 1000 pg/ml (> 1000; > 1000) and in group NS from 870 pg/ml (542; >1000) to > 1000 pg/ml (785; > 1000)]. IL-6 decreased in the NS group more slowly and therefore a significant difference in concentrations on day 5 was measured (p = 0.001). In group S a decrease from 74 pg/ml (32; 178) to 29.8 pg/ml (14.1; 57.4) and in group NS from 88 pg/ml (34; 681) to 66.5 pg/ml (43; 109) was measured. Patients with TNF-alpha production < 1000 pg/ml on day 1 had significantly greater mortality (p < 0.05) as did those with IL-10 > 9.2 pg/ml on day 1 (p = 0.06) and day 5 (p = 0.09). IL-6 >75 pg/ml predicted ICU death. No clinically significant association was found between any immunologic parameter and APACHE II on ICU admission.

Conclusion:
The extended immune spectrum (TNF-alpha production of the whole blood after LPS stimulation, IL-10 and IL-6 plasma concentrations) has a predictive value in the heterogeneous population of longterm ICU patients.

Keywords: intensive; immunoparalysis; TNF-alpha; interleukin 6; interleukin 10; APACHE II; outcome

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dadák L, Štouračová M, Štětka P, Kuklínek P, Šrámek V. Extended immunologic profile taken during the first days in the ICU and the prognosis of patients requiring long-term intensive care. Anest. intenziv. Med. 2007;18(3):164-169.
Download citation

References

  1. Nierhaus, A., Montag, B., Timmler, N. et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med., 2003, 29, p. 646-651. Go to original source... Go to PubMed...
  2. Monneret, G., Lepape, A., Voirin, N. et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med., 2006, 32, p. 1175-1183. Go to original source... Go to PubMed...
  3. Průcha, M., Herold, I., Zazula, R. et al. Monocytární deaktivace a produkce tumor nekrotizujícího faktoru ex vivo - prognostické parametry pacientů jednotek intenzivní péče. Anest. intenziv. Med., 2003, 14, s. 223-227.
  4. Monneret, G., Finck, M. E., Venet, F. et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett., 2004, 95, p. 193-198. Go to original source... Go to PubMed...
  5. Ploder, M., Pelinka, L., Schmuckenschlager, C. et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock, 2006, 25, p. 129-134. Go to PubMed...
  6. Oczenski, W., Krenn, H., Jilch, R. et al. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med., 2003, 29, p. 1253-1257. Go to original source... Go to PubMed...
  7. Allen, M. L., Peters, M. J., Goldman, A. et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit. Care Med., 2002, 30, p. 1140-1145. Go to original source... Go to PubMed...
  8. Allen, M. L., Hoschtitzky, J. A., Peters, M. J. et al. Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit. Care Med., 2006, 34, p. 2658-2665. Go to original source... Go to PubMed...
  9. Patel, R. T., Deen, K. I., Youngs, D. et al. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br. J. Surg., 1994, 81, p. 1306-1308. Go to original source... Go to PubMed...
  10. Geppert, A., Dorninger, A., Delle-Karth, G. et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit. Care Med., 2006, 34, p. 2035-2042. Go to original source... Go to PubMed...
  11. Taniguchi, T., Koido, Y., Aiboshi, J. et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit. Care Med., 1999, 27, p. 1262-1264. Go to original source... Go to PubMed...
  12. Watanabe, E., Hirasawa, H., Oda, S. et al. Cytokine-related genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J. Trauma, 2005, 59, p. 1181-1189. Go to original source... Go to PubMed...
  13. Meduri, G. U., Headley, S., Kohler, G. et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest, 1995, 107, p. 1062-1073. Go to original source... Go to PubMed...
  14. Holzheimer, R. G., Capel, P., Cavaillon, J. M. et al. Immunological surrogate parameters in a prognostic model for multi-organ failure and death. Eur. J. Med. Res., 2000, 5, p. 283-294.
  15. Stimac, D., Fisic, E., Milic, S. et al. Prognostic values of IL-6, IL-8, and IL-10 in acute pancreatitis. J. Clin. Gastroenterol., 2006, 40, p. 209-212. Go to original source... Go to PubMed...
  16. Marchant, A., Alegre, M. L., Hakim, A. et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J. Clin. Immunol., 1995, 15, p. 266-273. Go to original source... Go to PubMed...
  17. Dadak, L., Stouracova, M., Stetka, P., Sramek, V. Monocyte function (CD14+HLA-DR+) during first ICU days in long term ICU patients. Intensive Care Med., 2005, 31, suppl 1, S14.
  18. Dadák, L., Štouračová, M., Štětka, P., Kuklínek, P. Šrámek V. Aktivace monocytů během prvních dnů pobytu na JIP jako predikční marker přežití. Anest. intenziv. Med., 2007, 18, 3, s. 170-174.
  19. Hack, C. E., De Groot, E. R., Felt-Bersma, R. J. et al. Increased plasma levels of interleukin-6 in sepsis. Blood, 1989, 74, p. 1704-1710. Go to original source...
  20. Calandra, T., Gerain, J., Heumann, D. et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am. J. Med., 1991, 91, p. 23-29. Go to original source... Go to PubMed...
  21. Damas, P., Ledoux, D., Nys, M. et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg., 1992, 215, p. 356-362. Go to original source... Go to PubMed...
  22. Casey, L. C., Balk, R. A., Bone, R. C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med., 1993, 119, p. 771-778. Go to original source... Go to PubMed...
  23. Reinhart, K., Menges, T., Gardlund, B. et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit. Care Med., 2001, 29, p. 765-769. Go to original source... Go to PubMed...
  24. Hynninen, M., Pettila, V., Takkunen, O. et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock, 2003, 20, p. 1-4. Go to original source... Go to PubMed...
  25. Lowe, P. R., Galley, H. F., Abdel-Fattah, A., Webster, N. R. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit. Care Med., 2003, 31, p. 34-38. Go to original source... Go to PubMed...
  26. Venet, F., Bohe, J., Debard, A. L. et al. Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit. Care Med., 2005, 33, p. 2836-2840. Go to original source... Go to PubMed...
  27. Monneret, G., Debard, A. L., Venet, F. et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med., 2003, 31, p. 2068-2071. Go to original source... Go to PubMed...
  28. Weiss, M., Voglic, S., Harms-Schirra, B. et al. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med., 2003, 29, p. 904-914. Go to original source... Go to PubMed...
  29. Keh, D., Boehnke, T., Weber-Cartens, S. et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med., 2003, 167, p. 512-520. Go to original source... Go to PubMed...
  30. Moller, H. J., Moestrup, S. K., Weis, N.et al. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit. Care Med., 2006, 34, p. 2561-2566. Go to original source... Go to PubMed...
  31. Pangault, C., Le Tulzo, Y., Tattevin, P. et al. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit. Care Med., 2006, 34, p. 1193-1201. Go to original source... Go to PubMed...
  32. Fumeaux, T., Dufour, J., Stern, S., Pugin, J. Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines. Intensive Care Med., 2004, 30, p. 2028-2037. Go to original source... Go to PubMed...
  33. Clark, M. F., Baudouin, S. V. A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med., 2006, 32, p. 1706-1712. Go to original source... Go to PubMed...
  34. Volk, D. H., Reinke, P., Döcke, W. D. Immunostimulation with cytokines in patients with "immunoparalysis". In Marshall, J. C., Cohen, J. (Eds). Immune response in the critically ill. Berlín : Springer-Verlag 2000, p. 393-404. Go to original source...
  35. Záhorec, R. Diagnostika a monitorovanie septického syndromu - laboratorne skóre imunitnej zápalovej odpovede. Anest. neodkl. Péče. 2001, 12. Suppl. 1, s. 16-23.




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.